CancerenD24 Screening as an Aid to the Clinician for the Diagnosis of Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorTel-Aviv Sourasky Medical Center
About this trial
The purpose of the researchers is to test whether the CancerenD24 index, an algorithm based on the quantitative value of CD24, CD11b, clinical and laboratory characteristics, developed in the laboratory can help in the early detection of a malignant disease in a population of healthy subjects.
Eligibility criteria
Qualifiers
Completion of all medical exams and questionnaires including cancer diagnoses, demographic data and other epidemiologic information
Willing and able to sign an informed consent
Age ≥40 years
Disqualifiers
Age < 40 years
Pregnancy or breastfeeding
Any type of fever
Any cancer active at study entry or up to 5 years prior to study entry
Trial design
Treatments tested in this trial
- Blood-based liquid biopsy
Treatment groups
2,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Tel-Aviv Sourasky Medical Center
Lead sponsor
Tel Aviv Medical Center
Collaborator
Source ClinicalTrials.gov